Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Akero Therapeutics Inc
(NQ:
AKRO
)
23.50
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Akero Therapeutics Inc
< Previous
1
2
3
4
5
Next >
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors
May 02, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
AKRO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit
May 02, 2024
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors
May 02, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Akero Therapeutics (AKRO) Slides After Failed Trial, Hit With Class Action Lawsuit – Hagens Berman
May 02, 2024
From
Hagens Berman Sobol Shapiro LLP
Via
GlobeNewswire
AKRO INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO
May 01, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
NASDAQ: AKRO: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Akero Therapeutics, Inc.
April 30, 2024
From
Kessler Topaz Meltzer & Check, LLP
Via
Business Wire
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
April 30, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Stockholder Alert: Robbins LLP Informs Investors of the Class Action Filed Against Akero Therapeutics, Inc. (AKRO)
April 30, 2024
From
Robbins LLP
Via
GlobeNewswire
AKERO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Akero Therapeutics, Inc. and Encourages Investors to Contact the Firm
April 29, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO
April 29, 2024
From
Rosen Law Firm
Via
Business Wire
AKRO INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit
April 29, 2024
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc.with Losses to Contact the Firm
April 28, 2024
From
Schall Law
Via
GlobeNewswire
AKERO THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO
April 28, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
AKRO Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Akero Therapeutics (NASDAQ:AKRO)
March 20, 2024
From
Abraham, Fruchter & Twersky, LLP
Via
GlobeNewswire
Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
March 08, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
March 07, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
March 05, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics Announces Proposed Public Offering of Common Stock
March 04, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
March 04, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
February 29, 2024
Investor webcast on Monday, March 4 at 8:00 a.m. ET to present clinical data
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 29, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
December 18, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023
November 10, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
November 08, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference
October 17, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and
October 10, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
October 09, 2023
Investor webcast on Tuesday, October 10 at 8:00 a.m. ET to present clinical data
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology
October 04, 2023
From
Akero Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.